ACE2 and COVID-19: Our first attempt to generate a COVID-19 vaccine was based on producing a recombinant RBD in human eukaryotic cells and chemically coupling the domain to CuMVTT-VLPs, resulting in a vaccine candidate that binds to ACE2 and induces neutralizing antibodies in mice [20].